Retinal and choroidal neovascularization

The unique vascular supply of the retina, the ability to visualize the vasculature in vivo, and the ability to selectively express genes in the retina make the retina an ideal model system to study molecular mechanisms of angiogenesis. In addition, this area of investigation has great clinical significance, because retinal and choroidal neovascularization are the most common causes of severe visual loss in developed countries and new treatments are needed. As a result, interest in ocular neovascularization is rapidly growing and there has been considerable recent progress. Use of genetically engineered mice in recently developed murine models provides a means to investigate the role of individual gene products in neovascularization in two distinct vascular beds, the retinal vasculature and the choroidal vasculature. It appears that angiogenesis in different vascular beds has common themes, but also has tissue‐specific aspects. This review summarizes recent progress in the field of ocular neovascularization and the prospects that it provides for the development of new treatments. J. Cell. Physiol. 184:301–310, 2000. © 2000 Wiley‐Liss, Inc.

[1]  R Hiller,et al.  Blindness caused by diabetic retinopathy. , 1974, American journal of ophthalmology.

[2]  P. Campochiaro,et al.  Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. , 1999, The American journal of pathology.

[3]  E. de Juan,et al.  Altered distribution of basic fibroblast growth factor in diabetic retinopathy. , 1991, Archives of ophthalmology.

[4]  A. Sorsby,et al.  A FUNDUS DYSTROPHY WITH UNUSUAL FEATURES (Late onset and dominant inheritance of a central retinal lesion showing oedema, haemorrhage and exudates developing into generalised choroidal atrophy with massive pigment proliferation) , 1949 .

[5]  D. Eliott,et al.  Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. , 1996, American journal of ophthalmology.

[6]  D. S. Mcleod,et al.  Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy. , 1996, Investigative ophthalmology & visual science.

[7]  M. Gertsenstein,et al.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.

[8]  P. Campochiaro,et al.  Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. , 1999, Investigative ophthalmology & visual science.

[9]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[10]  J. Stone,et al.  Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  G. Brown,et al.  Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. , 1990, Archives of ophthalmology.

[12]  P. Campochiaro,et al.  Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. , 2000, The American journal of pathology.

[13]  J. Stone,et al.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.

[14]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.

[15]  J. Rossant,et al.  The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. , 1995, The EMBO journal.

[16]  P. Campochiaro,et al.  Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. , 1997, Histology and histopathology.

[17]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[18]  M. P. Hartmann,et al.  Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. , 1994, Current eye research.

[19]  Chandra L. Theesfeld,et al.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Campochiaro,et al.  Role of hypoxia and extracellular matrix‐integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells , 1999 .

[21]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[23]  T. L. Murphy,et al.  Effect of Intravitreal Administration of Indomethacin on Experimental Subretinal Neovascularization in the Subhuman Primate , 1995 .

[24]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[25]  R. O. Poyton,et al.  Oxygen sensing and molecular adaptation to hypoxia. , 1996, Physiological reviews.

[26]  T. Ishibashi,et al.  Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. , 1985, Archives of ophthalmology.

[27]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[28]  P. D'Amore,et al.  Mechanisms of retinal and choroidal neovascularization. , 1994, Investigative ophthalmology & visual science.

[29]  N. Ashton,et al.  Role of Oxygen in the Genesis of Retrolental Fibroplasia , 1953, The British journal of ophthalmology.

[30]  E S Gragoudas,et al.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.

[31]  E. Keshet,et al.  Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[32]  Joan W. Miller,et al.  Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. , 1996, Archives of ophthalmology.

[33]  K. Plate,et al.  Angiogenesis in Embryos and Ischemic Diseases , 1997, Thrombosis and Haemostasis.

[34]  G. Lutty,et al.  Localization of vascular endothelial growth factor in human retina and choroid. , 1996, Archives of ophthalmology.

[35]  M. Uyama,et al.  Expression of basic fibroblast growth factor mRNA in developing choroidal neovascularization. , 1996, Current eye research.

[36]  R W Flower,et al.  Visualization of a developing vasculature. , 1987, Microvascular research.

[37]  N. Ashton.  Retinal vascularization in health and disease: Proctor Award Lecture of the Association for Research in Ophthalmology. , 1957, American journal of ophthalmology.

[38]  Lois E. H. Smith,et al.  Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor , 1999, Nature Medicine.

[39]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[40]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[41]  Joan W. Miller,et al.  Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. , 1994, The American journal of pathology.

[42]  Y Ikada,et al.  A new model of subretinal neovascularization in the rabbit. , 1995, Investigative ophthalmology & visual science.

[43]  P. Campochiaro,et al.  Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. , 1998, The American journal of pathology.

[44]  P. Campochiaro,et al.  Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. , 1998, The American journal of pathology.

[45]  P. Maher,et al.  High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells--implications for the modulation of FGF-2 , 1995, The Journal of cell biology.

[46]  Joan W. Miller,et al.  Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. , 1994, American journal of ophthalmology.

[47]  Lois E. H. Smith,et al.  Essential role of growth hormone in ischemia-induced retinal neovascularization. , 1997, Science.

[48]  P. Campochiaro,et al.  Increased vascular endothelial growth factor (VEGF) and transforming growth factorβ (TGF β ) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization , 1998, Journal of Neuroimmunology.

[49]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[50]  P. Campochiaro,et al.  Bone morphogenetic proteins-2 and -4: negative growth regulators in adult retinal pigmented epithelium. , 2000, Investigative ophthalmology & visual science.

[51]  P. Campochiaro,et al.  Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina , 1999, Journal of cellular physiology.

[52]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[53]  M. Killingsworth,et al.  Macrophages related to Bruch's membrane in age-related macular degeneration , 1990, Eye.

[54]  K. Gitter,et al.  Presumed macular choroidal watershed vascular filling, choroidal neovascularization, and systemic vascular disease in patients with age-related macular degeneration. , 1998, American journal of ophthalmology.

[55]  S. Seregard,et al.  Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.

[56]  C. Puliafito,et al.  A new model of experimental choroidal neovascularization in the rat. , 1989, Archives of ophthalmology.

[57]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[58]  R. Frank,et al.  A model of subretinal neovascularization in the pigmented rat. , 1989, Current eye research.

[59]  A. Patz,et al.  Oxygen studies in retrolental fibroplasia. II. The production of the microscopic changes of retrolental fibroplasia in experimental animals. , 1953, American journal of ophthalmology.

[60]  P. Campochiaro,et al.  Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood– Retinal Barrier in Rabbits and Primates , 1997 .

[61]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[62]  E S Gragoudas,et al.  Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.

[63]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[64]  P A D'Amore,et al.  Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells , 1987, The Journal of cell biology.

[65]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[66]  S. Apte,et al.  The Gene Structure of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Its Inhibitory Activities Define the Distinct TIMP Gene Family (*) , 1995, The Journal of Biological Chemistry.

[67]  D. Shima,et al.  Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability , 1995, FEBS letters.

[68]  Lois E. H. Smith,et al.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[69]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P. Campochiaro,et al.  Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. , 1997, The American journal of pathology.

[71]  A. Ho,et al.  Foveolar choroidal blood flow in age-related macular degeneration. , 1998, Investigative ophthalmology & visual science.

[72]  S. Ryan,et al.  Subretinal neovascularization. Natural history of an experimental model. , 1982, Archives of ophthalmology.

[73]  A. Bird,et al.  Sorsby's pseudoinflammatory macular dystrophy. , 1981, The British journal of ophthalmology.

[74]  D. Hinton,et al.  Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.

[75]  P. Campochiaro,et al.  Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy. , 2000, The American journal of pathology.

[76]  A. Bird,et al.  Sorsby's fundus dystrophy. A light and electron microscopic study. , 1989, Ophthalmology.

[77]  R. Pruett,et al.  Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy , 1994, Nature Genetics.

[78]  K Muraoka,et al.  Midperipheral fundus involvement in diabetic retinopathy. , 1981, Ophthalmology.

[79]  P. Campochiaro,et al.  Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[80]  S. Ryan,et al.  The role of retinal pigment epithelium in the involution of subretinal neovascularization. , 1986, Investigative ophthalmology & visual science.

[81]  R. Frank,et al.  Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. , 1994, Investigative ophthalmology & visual science.

[82]  H. Hammes,et al.  Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor–type integrins inhibits retinal neovascularization , 1996, Nature Medicine.

[83]  W R Green,et al.  Age-related Macular Degeneration Histopathologic Studies: The 1992 Lorenz E. Zimmerman Lecture , 1993, Ophthalmology.

[84]  W. Green,et al.  Granulomatous reaction to Bruch's membrane in age-related macular degeneration. , 1994, Archives of ophthalmology.

[85]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[86]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[87]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[88]  Lois E. H. Smith,et al.  Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[89]  A. Bird,et al.  Sorsby's pseudoinflammatory macula dystrophy—Sorsby's fundus dystrophies , 1988, Eye.

[90]  R. Danis,et al.  Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. , 1998, Investigative ophthalmology & visual science.

[91]  J. Folkman,et al.  Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[92]  A Mathis,et al.  Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. , 1994, Archives of ophthalmology.

[93]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.